Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). 2023.

Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open. 2020;3: e2013226.

Article  PubMed  PubMed Central  Google Scholar 

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

Article  CAS  PubMed  Google Scholar 

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

Article  CAS  PubMed  Google Scholar 

Geyer CE Jr, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37.

Article  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2020;6:367–74.

Article  PubMed  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816–37.

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer. 2023; 2023.

Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010;116:3112–8.

Article  CAS  PubMed  Google Scholar 

Bhargava R, Dabbs DJ. The story of the Magee equations: the ultimate in applied immunohistochemistry. Appl Immunohistochem Mol Morphol. 2022. https://doi.org/10.1097/PAI.0000000000001065.

Article  PubMed  PubMed Central  Google Scholar 

Orucevic A, Bell JL, King M, McNabb AP, Heidel RE. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast. 2019;46:116–25.

Article  PubMed  Google Scholar 

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–8.

Article  PubMed  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of Malignant Tumours, 8th ed. John Wiley & Sons; 2017.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.

Article  CAS  PubMed  Google Scholar 

Lee SB, Kim J, Sohn G, Kim J, Chung IY, Kim HJ, et al. A Nomogram for predicting the oncotype DX recurrence score in women with T1–3N0-1miM0 hormone receptor-positive, Human Epidermal Growth Factor 2 (HER2)-negative breast cancer. Cancer Res Treat. 2019;51:1073–85.

Article  CAS  PubMed  Google Scholar 

Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23(Suppl 2):S52–9.

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–22.

Article  CAS  PubMed  Google Scholar 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1–73.

Article  Google Scholar 

Yoo SH, Kim TY, Kim M, Lee KH, Lee E, Lee HB, et al. Development of a nomogram to predict the recurrence score of 21-gene prediction assay in hormone receptor-positive early breast cancer. Clin Breast Cancer. 2020;20(98–107): e1.

Google Scholar 

Kim MC, Kwon SY, Choi JE, Kang SH, Bae YK. Prediction of oncotype DX recurrence score using clinicopathological variables in estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. J Breast Cancer. 2023;26:105–16.

Article  PubMed  PubMed Central  Google Scholar 

Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol Oncol Stem Cell Ther. 2016;9:48–54.

Article  CAS  PubMed  Google Scholar 

Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131:413–24.

Article  CAS  PubMed  Google Scholar 

Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, et al. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. Breast Cancer. 2015;22:406–12.

Article  PubMed  Google Scholar 

Kim JM, Ryu JM, Kim I, Choi HJ, Nam SJ, Kim SW, et al. Verification of a Western nomogram for predicting oncotype DX recurrence scores in Korean patients with breast cancer. J Breast Cancer. 2018;21:222–6.

Article  PubMed  PubMed Central  Google Scholar 

Davey MG, Jalali A, Ryan EJ, McLaughlin RP, Sweeney KJ, Barry MK, et al. A novel surrogate nomogram capable of predicting OncotypeDX recurrence score(c). J Pers Med. 2022. https://doi.org/10.3390/jpm12071117.

Article  PubMed  PubMed Central  Google Scholar 

Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, et al. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. BMC Health Serv Res. 2014;14:372.

Article  PubMed  PubMed Central  Google Scholar 

Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node–negative, estrogen-receptor–positive, early-stage breast cancer. Am J Manag Care. 2005;11:313–24.

PubMed  Google Scholar 

Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal. J Clin Oncol. 2018;36:1619–27.

Article  PubMed  PubMed Central